Amarin Corp Plc (AMRN)

[ziploc_1]

Pfizer could well employ Vascepa to help REDUCE THE CYTOKINE RESPONSE RATE, which occurs with its drug Elrexfio...
"PFE: Pfizer wins FDA nod for multiple myeloma therapy...
Pfizer (NYSE:PFE) announced Monday that the U.S. FDA granted accelerated approval for its immunotherapy Elrexfio for adults with relapsed or refractory multiple myeloma who have received at least four lines of therapy.
However, the company will have to prove its clinical benefit in confirmatory trial (s) for continued approval of the therapy....Elrexfio, a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody, comes with a Boxed Warning for safety concerns, namely cytokine release syndrome (CRS)"